Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has submitted a Clinical Trial Application (“CTA”) for its anti-cancer technology to Health Canada for approval.

Theralase’s anti-cancer technology utilizes the proprietary Theralase TLC-3200 Oncology Laser System to activate the Company’s lead Photo Dynamic Compound (“PDC”), TLD-1433, to treat Non-Muscle Invasive Bladder Cancer (“NMIBC”).

Pending approval of the following applications, Theralase plans to commence enrolling patients inflicted with NMIBC into a Phase Ib clinical study at Princess Margaret Cancer Center, University Health Network (“UHN”) to prove the primary objective of safety and tolerability, with an exploratory objective of efficacy:

1. UHN Research Ethics Board (“REB”);
2. Health Canada CTA;
3. Health Canada Investigational Testing Authorization (“ITA”).

Roger Dumoulin-White, President and CEO, Theralase stated, “The submission of a CTA to Health Canada for NMIBC marks completion of another major milestone for the Company on our way to prove the safety, tolerability and efficacy of our anti-cancer technology in the destruction of numerous cancers, commencing with NMIBC. Pending approval of the CTA, ITA and REB, UHN will commence enrolling and treating patients inflicted with this deadly disease.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com .

Theralase Technologies Inc. was recognized as a TSX Venture 50® company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Michael Borovec

Director of Investor Relations

1.866.THE.LASE (843-5273) ext. 222

416.699.LASE (5273) ext. 222

mborovec@theralase.com

www.theralase.com

To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/theralase09172015.pdf

Source: Theralase Technologies Inc. (TSX Venture:TLT, OTC Pink:TLTFF) http://theralase.com/

Maximum News Dissemination by FSCwire. http://www.fscwire.com

Copyright © 2015 Filing Services Canada Inc.